摘要
目的:评价R-CHOP方案治疗老年弥漫大B细胞淋巴瘤(DLBCL)患者的疗效及不良反应。方法:观察25例70～86岁DLBCL患者,用R-CHOP方案治疗8疗程,之后用美罗华单药维持(每3个月1次,维持2年);分析化疗的疗效及不良反应。结果:19例达到完全缓解(CR),6例达到部分缓解(PR),无严重的不良反应。12例完成美罗华单药维持治疗2年者,随访未见复发。结论:美罗华联合化疗治疗高龄DLBCL药物耐受好,不良反应小。
Objective： To evaluate the therapeutic effect and adverse reaction of rituximab in combination with CHOP （ R-CHOP） for the elderly patients with diffuse large B-cell lymphoma （ DLBCL） . Methods： Twenty-five elderly patients aged 75 ～ 80 with DLBCL were observed. Eight cycles of R-CHOP had been taken for every patients and maintenance therapy of single dose Mabthera had been used every 3 months and lasted for 2 years. The therapeutic effect and adverse reaction were analyzed. Results： Nineteen cases achieved complete remission （ CR） and 6 cases achieved partial remission （ PR） ,no serious adverse reaction had been observed. Twelve patients who had completed maintenance therapy of Mabthera for 2 years showed no recurrence in the follow-up. Conclusion： Combination of Mabthera with chemotherapy are well tolerated by elderly patients with DLBCL and without serious adverse reaction.
出处
《内科急危重症杂志》
2011年第6期351-352,共2页
Journal of Critical Care In Internal Medicine
